NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.02
+6.17%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$5.87
From 52W high−57.81%
Volume83709.00
Market cap$27.56M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$5.87
From 52W high
−57.81%
Volume
83709.00
Market cap
$27.56M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
44.8
MomentumView details →
1D Return
+6.17%
YTD Return
−57.72%
SummaryUpdated Jun 1, 2026
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Similar companies
Latest newsMore news →
NextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.17d agoXcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.41d agoAvere, an investee of Hansoh Pharmaceutical, merges into NextCure via a merger agreement, with Hansoh expected to hold more than 30% of the combined entity's equity.68d ago